中文摘要：
只有一部分非小细胞肺癌（NSCLC）患者对免疫疗法有反应，这凸显了迫切需要开发改善患者疗效的治疗策略。我们开发了一种化学正向调节剂（HEI3090），作用于嘌呤能P2RX7受体，可增强αPD-1治疗，从而在可移植和致癌基因诱导的小鼠模型中有效控制肺肿瘤的生长，并触发持久的抗肿瘤免疫反应。在机制上，该分子刺激表达P2RX7的树突状细胞生成IL-18，进而促使肿瘤内的自然杀伤细胞和CD4⁺ T细胞产生IFN-γ。与免疫检查点抑制剂联合使用时，该分子可在80%的LLC肿瘤小鼠中诱导肿瘤消退。小鼠在肿瘤再挑战时也能受到保护，这种保护依赖于CD8⁺ T细胞。因此，小分子P2RX7激活剂与免疫检查点抑制剂的联合治疗代表了一种可能对NSCLC有效的策略。
英文摘要：
Only a subpopulation of non-small cell lung cancer (NSCLC) patients responds to immunotherapies, highlighting the urgent need to develop therapeutic strategies to improve patient outcome. We develop a chemical positive modulator (HEI3090) of the purinergic P2RX7 receptor that potentiates αPD-1 treatment to effectively control the growth of lung tumors in transplantable and oncogene-induced mouse models and triggers long lasting antitumor immune responses. Mechanistically, the molecule stimulates dendritic P2RX7-expressing cells to generate IL-18 which leads to the production of IFN-γ by Natural Killer and CD4+ T cells within tumors. Combined with immune checkpoint inhibitor, the molecule induces a complete tumor regression in 80% of LLC tumor-bearing mice. Cured mice are also protected against tumor re-challenge due to a CD8-dependent protective response. Hence, combination treatment of small-molecule P2RX7 activator followed by immune checkpoint inhibitor represents a strategy that may be active against NSCLC.
论文信息：
论文题目：A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy
期刊名称：Nature Communications
时间期卷：12, Article number: 653 (2021)
在线时间：2021年1月28日
DOI： doi.org/10.1038/s41467-021-20912-2
产品信息：
货号：C-005
规格：5ml
品牌：Liposoma
产地：荷兰
名称：Clodronate Liposomes
办事处：Target Technology(靶点科技)
Clodronate Liposomes氯膦酸盐脂质体清除肺肿瘤细胞模型巨噬细胞，荷兰Liposoma巨噬细胞清除剂ClodronateLiposomes见刊于Nature Communications：一种小分子P2RX7激活剂促进抗肿瘤免疫反应并使肺肿瘤对免疫疗法更敏感。
Liposoma巨噬细胞清除剂Clodronate Liposomes氯膦酸二钠脂质体清除肺脏巨噬细胞的材料和方法：
材料和方法文献截图：
